Home / Market News / $NIKI
benzinga Corporate Catalyst Impact 55/100 ● neutral

Niki BioSolutions' DiamiR Biosciences Subsidiary To Perform Apolipoprotein E Genotyping On Plasma Samples From Global Alzheimer’s Platform Foundation Bio-Hermes-002 Trial Group

Oct 14, 2026, 12:03 PM UTC · Primary ticker $NIKI

Niki BioSolutions' subsidiary, DiamiR Biosciences, will perform APOE genotyping on plasma samples for the Bio-Hermes-002 Alzheimer's study. This collaboration highlights DiamiR's specialized capabilities in genetic risk factor analysis for Alzheimer's disease, potentially enhancing its profile and future business opportunities.

Niki BioSolutions announced that its subsidiary, DiamiR Biosciences, will conduct APOE genotyping for the Global Alzheimer’s Platform Foundation’s Bio-Hermes-002 study. This is significant because the APOE ε4 allele is a major genetic risk factor for late-onset Alzheimer's, and this genotyping provides crucial information for clinical trial design and risk assessment for anti-amyloid therapies. For Niki BioSolutions, this collaboration validates DiamiR's expertise and technology, potentially leading to increased recognition and future contracts in the Alzheimer's research space. In the short term, it's a positive operational development, while long-term implications could include DiamiR becoming a more sought-after partner for genetic analysis in neurological disorders, offering a growth opportunity for NIKI.

$NIKI positive Subsidiary collaboration on significant study
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.